Immunic (IMUX)
(Delayed Data from NSDQ)
$1.25 USD
0.00 (0.00%)
Updated May 28, 2024 04:00 PM ET
After-Market: $1.25 0.00 (0.00%) 7:10 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 21 - 40 ( 213 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Highlights From Celiac Disease R&D Event; Part C of Ph1 Study Expected Mid-23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Assuming at OP; Focusing In On IMU-838''s Best-In-Class Potential for MS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
MS KOL Call and Event Highlights; New Ph2 EMPhASIS Data for IMU-838/RRMS
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Next Steps for IMU-935/Psoriasis in Q1:23; Q3 Financials; Pipeline Progress
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Highlights: A stIMUlating Conversation on IMU-935/ Psoriasis
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
High Placebo Response in Ph1 IMU-935/Psoriasis Trial; Focus Turns to Pipeline
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Financing Overhang Removed Sets the Stage for IMU-935 Psoriasis Results This Month; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SINGH G
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Ph1 SAD/MAD Results for IMU-856 Demonstrate Promising Safety, Tolerability & PK
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Ocrevus-Like Neuroprotection With IMU-838 Sets Up MS Opportunity; Assume Coverage With Buy Rating & $26 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department